In Summary, for those who received DAPT:

Benefits in NNT

    1.6% of patients avoided one major adverse cardiac event
    0.5% of patients avoided cardiovascular death
    1 in 63 patients avoided one major adverse cardiac event
    1 in 219 patients avoided cardiovascular death

Harms in NNT

    None experienced an additional major bleeding complication
    None experienced an additional major bleeding complication

View As:

Source: Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37(4):390–399.

Study Population: Adults with stent implantation following myocardial infarction (MI) and concurrent treatment with dual antiplatelet therapy (DAPT)—the combination of aspirin and a P2Y12 inhibitor

Efficacy Endpoints: Prevention of major adverse cardiac events, defined as cardiovascular and noncardiovascular death, MI, and stroke

Harm Endpoints: Major bleeding complications

Narrative: More than 1 million Americans are diagnosed with an MI every year.1 Risk of atherothrombosis increases significantly after an MI, with an increase in platelet activation that can last for years.1 Frequent placement of drug-eluting stents in these patients further increases the risk of thrombosis. Because of this increased thrombotic risk, DAPT is used for long-term secondary prevention of major cardiac events.2,3,4 The duration of DAPT has been debated over the past few years. Prolonged (more than 12 months) DAPT has been shown to increase mortality in patients with drug-eluting stents despite a reduced rate of MI and stent thrombosis.5 However, recent studies suggest that the use of prolonged DAPT after an MI, regardless of stent placement or type, improves cardiovascular mortality without a significant increase in bleeding risk.5

A 2016 meta-analysis, including three randomized controlled trials with a total of 21,534 patients post-MI, compared those who received DAPT for 12 months and those who received continuous treatment beyond one year, with mean follow-up of 2.5 years.5 Patients were randomized at least one year after their infarction with a minimum of two years follow-up. There were significantly lower rates of major cardiac events among those who used prolonged DAPT (number needed to treat [NNT] = 63). Of note, overall cardiovascular mortality was significantly improved (NNT = 219). Despite a numerical increase in complications with prolonged DAPT vs. non–prolonged DAPT, there was no statistical significance between treatment groups for major bleeding (N = 207 vs. 134) or fatal bleeding (N = 29 vs. 26). In patients who are stable one year post-MI, prolonged use of DAPT may be an effective treatment to decrease major cardiac events and cardiovascular mortality.

Caveats: Despite the evidence to support the use of prolonged DAPT in stable patients one year after an MI, there is still some debate as to the clinical relevance of these data. The American College of Cardiology and American Heart Association summarize the data as “moderately strong evidence of reduced cardiovascular events at the expense of increased bleeding.”4 This statement can be misleading because although it is based on a 2015 meta-analysis that shows a statistically significant increase in major bleeding (number needed to harm = 132), there was a nonsignificant increase in fatal bleeding. Additionally, this study demonstrated a reduction in cardiovascular death (NNT = 380) and no increase in noncardiovascular death or all-cause mortality.2 The data for this study come from the same randomized controlled trials in the 2016 meta-analysis with the addition of three additional trials (11,901 additional patients). These trials are not specifically discussed in the 2016 meta-analysis; however, it does point out that five articles were excluded because of incomplete data or nonrelevance.

The 2016 meta-analysis is limited by its lack of access to sufficient patient demographics to identify specific subgroups with higher therapy benefit or increased risk of harm. Additionally, it does not account for the presence or type of stents that patients may have received over the course of the study.

Author: Matthew K. Hawks, MD, PhD and Mark A. Dixon, PhD, LCSW

Published/Updated: October 1, 2017

  1. The Title Bar

    The title bar is color-coded with our overall recommendation.

    • Green: Benefits outweigh risks.
    • Yellow: Unclear risk/benefit profile.
    • Red: Benefits do not outweigh risks.
    • Black: Obvious harms, no clear benefits.
  2. Tip content...